Q4 2025 Aurinia Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2026 / 01:30 PM GMT

Release Date Price: €11.79 (-3.04%)

Transcript 10-K8-K

Key Points

Positve

Aurinia Pharmaceuticals Inc (AUPH) reported a 29% increase in total revenue for Q4 2025 compared to the same period in 2024.
Net product sales of Lukiness grew by 25% year-over-year, indicating strong market demand.
The company achieved a significant increase in net income for Q4 2025, up 14,957% from the previous year, primarily due to the release of its valuation allowance on deferred tax assets.
Cash flows from operating activities increased by 52% in Q4 2025 compared to Q4 2024, reflecting improved operational efficiency.
Aurinia Pharmaceuticals Inc (AUPH) has initiated a clinical study of Ari intercept in one autoimmune disease and plans to start another in the first half of 2026, showing progress in their pipeline development.

Negative

The guidance for 2026 appears conservative despite strong Q4 2025 performance, raising questions about future growth assumptions.
The company terminated the phase 3 and open-label studies in the vocal study due to recruitment challenges, indicating potential setbacks in clinical development.
There is uncertainty regarding the competitive impact of new entrants like Gazaga in the lupus nephritis market.
Aurinia Pharmaceuticals Inc (AUPH) faces challenges in achieving global market penetration similar to the US due to varying pricing and reimbursement landscapes.
The company is not providing specific commercial metrics, which may limit transparency for investors.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AUPH.OQ - Aurinia Pharmaceuticals Inc
Q4 2025 Aurinia Pharmaceuticals Inc Earnings Call
Feb 26, 2026 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. Welcome to the Areia Pharmaceuticals 4th quarter and full year 2025 conference call. Please be advised that a Q&A session will follow Areia's prepared remarks, and we ask you to please ask one question and one follow-up, then return to the queue. I will now turn the call over to Peter Greenleaf, President and Chief Executive Officer of Oria.

Peter, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good morning. We want to thank you all for joining us today to discuss Arenia's 4th quarter and full year 2025 update.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.